Wolfe Research Starts First Tracks Biotherapeutics (TRAX) at Outperform Aug 18, 2026 05:39AM
First Tracks Biotherapeutics, Inc. (TRAX) Reports Q2 Loss of $0.95 Aug 13, 2026 04:19PM
First Tracks Biotherapeutics (TRAX) PT Raised to $95 at Piper Sandler Aug 13, 2026 09:24AM
H.C. Wainwright Reiterates Buy Rating on First Tracks Biotherapeutics (TRAX) Jul 9, 2026 06:50AM
Wells Fargo Starts First Tracks Biotherapeutics (TRAX) at Overweight Jun 8, 2026 05:00AM


May 4, 2026 02:16AM Piper Sandler Starts First Tracks Biotherapeutics (TRAX) at Overweight
Apr 28, 2026 06:04AM H.C. Wainwright Starts First Tracks Biotherapeutics (TRAX) at Buy
Apr 24, 2026 07:08AM Wedbush Starts First Tracks Biotherapeutics (TRAX) at Outperform
Apr 24, 2026 06:07AM Leerink Partners Starts First Tracks Biotherapeutics (TRAX) at Outperform
Apr 23, 2026 12:58AM JPMorgan Starts First Tracks Biotherapeutics (TRAX) at Overweight
Apr 22, 2026 02:51AM Barclays Starts First Tracks Biotherapeutics (TRAX) at Overweight
Apr 21, 2026 03:18AM UBS Starts First Tracks Biotherapeutics (TRAX) at Buy
Mar 31, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
Mar 4, 2026 06:45AM AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright
Mar 4, 2026 05:48AM Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'